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ABSTRACT
Cancer immunotherapy is a form of treatment protocol for cancer patients that has been
studied intensively over the last two decades. The undesirable side effects during the course
of conventional treatment has lead to the development of immunotherapy as an alternative
treatment modality. This approach encompasses the use of three different strategies with
various immunotherapeutic modalities including (i) cytokines and monoclonal antibodies; (ii)
activation of antigen presentation cells (APC) by using antigen-specific peptides or sources
of antigens such as tumour lysate; and finally (iii) adoptive transfer of ex vivo activated
autologous cytotoxic T-cells. Due to specific-targeting by antigen-specific monoclonal
antibodies, dendritic cells and activated CD8+ T-cells, immunotherapy can eliminate tumour
cells efficiently but the normal tissues are unaffected. Despite years of investigation, the
outcome of immunotherapy-based clinical trials are inconsistent with very low response
rates from patients. Several mechanisms have been proposed to contribute to this failure
including the presence of regulatory T-cells (Treg), immunomodulatory cytokines, and aberrant
gene expression in tumour cells. This review summarises information from about 140 articles
and review papers. In addition, it also provides an update on recent trends in combinational
immunotherapy with conventional therapy and encouraging results have been obtained. Re-
evaluation of previous studies is necessary to fine-tune the design and approach of
immunotherapy to ensure better treatment outcomes.
Keywords: Immunotherapy, cancer, combinational immunotherapy
INTRODUCTION
Immunotherapy is a form of clinical management procedure to enhance the defence
mechanism of patients either specifically or non-specifically to fight against disease.
Historically, the idea of immunotherapy was initiated a long time ago in the 1890s by Coley
who attempted to use bacterial toxins to treat cancer patients.[1] Tumour regression was
observed in those patients who received the injection. This could have been due to the
effect of cytokines upon induction of a non-specific stimulation of the immune response
towards the foreign antigen, the bacterial toxin.[1] Until today, Coley’s idea of a general
stimulation of the immune system by using bacterial agents has been applied to malignancy.
For example, Bacillus Calmette Guerin (BCG) has been tested and used as an adjuvant
together with either immunotherapy or chemotherapy to treat patients with superficial bladder
cancers.[2] In addition, the potency of using virus-derived substances and various chemicals
have also been investigated.[3, 4]
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There are three different approaches of immunotherapy to enhance the cellular immune
system for immunosurveillance (Fig. 1). Firstly, synthetic cytokines, interleukins or antibodies
are used to enhance the immune system in general. For example, interleukin-2 (IL-2) and
interferon γ and α have been used to treat systemic malignancy such as multiple myeloma[5]
and breast cancer.[6]  Secondly, the immune system can be activated specifically by optimising
antigen presentation. Administration of biologic modifiers such as antigen-specific peptide
or whole tumour cells are able to enhance endogenous antigen presentation of the epitope
by professional antigen presenting (APC) cells to CD8+ T cells. The third approach is to
restore the immune system by adoptive transfer of ex vivo activated effector cells. The
effector cells will first be stimulated against the tumour antigens of tumour cells in vitro
before being infused back into the patients. Examples of immunotherapeutic agents that
have been used in various immunotherapeutic settings are shown in Table 1.
BENEFITS OF IMMUNOTHERAPY
Radiotherapy, chemotherapy and surgery are the standard protocols to treat or to ensure
better quality of time for patients with neoplasms. Surgery helps to reduce tumour burden,
radiotherapy eliminates residual tumour cells in the surgical field and chemotherapy eliminates
micro-metastatic disease both systematically as well as in the surgical field.[7]  Despite their
roles in tumour tissue eradication, these conventional protocols are associated with a
number of side effects that may slowly deteriorate the normal physiological functions
especially the immune defence mechanism of the patients. Besides eradication of tumour
cells, both radiotherapy and chemotherapy can kill normal proliferating cells, including
those in the bone marrow, hair follicles and lining of the gastrointestinal tract. During the
course of conventional treatments, patients are vulnerable to infection as the immune system
of the patient is weak due to toxicity.
  To date, immunotherapy has moved from test tubes in the laboratory to the pre-
clinical and clinical level.[8] Table 2 shows the list of clinical trials that involve immunotherapy.
Immunotherapy helps to overcome several obstacles faced by conventional treatments,
including, lack of specificity and toxicity.[9] Furthermore, immunotherapy has the ability to
provide memory response to combat tumour reoccurrence.[7] Immunotherapy may provide
a better quality of time and reduce the psychological burden for the patients. As for those
patients who fail in their conventional therapy, when death appears to be inevitable,
immunotherapy may provide better treatment outcomes for them.
It is without doubt that surgery is a useful approach for cancer treatment.  However, it
has been shown that surgical procedures can lead to post-operative immunosuppression,
which may facilitate dissemination of tumour cells and outgrowth of minimal residual disease
or micro metastasis.[10] Therefore, strategies for stimulation of anti-tumour immune responses
are particularly crucial to prevent metastasis formation and reduce risk of relapse. In patients
with esophageal cancer who underwent trasthoracic esophaectomy, ex-vivo activated
lymphokine-activated killer (LAK) cells were transferred just after surgery to overcome the
post-operative immunosuppression.[11] According to Yamagchi and colleagues, LAK cells
transfer can significantly increase the helper and cytotoxic T-cell populations in post-
operative patients. In addition, the LAK cell treated group had a trend of reduction for post-
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 Table 1. List of Immunotherapeutic agents used
Immuntherapeutic agents Reference
Dendritic cells
- loaded with peptide [98]
- loaded with tumour lysate [99]
- pulse with necrotic tumour cells [100]
- loaded with irradiated tumour cells [101]
- pulsed with recombinant viral vector [102]
- pulsed with fusion protein [103]
- transfected with recombinant viral vector [104]
Monoclonal antibody
- antibody alone (anti-CCR4, anti-CD25, anti-CD20, etc) [105]
- fused with bacterial toxin [98,106]
- bispecific [107]
- genetically engineered [62]
- radioactive labeled [17]
Whole cell vaccine
- irradiated tumour cells [108]
- irradiated tumour cells transduced with viral vector [109]
- modified by virus [110]
Gene-modified
- cytotoxic T-cells (Supernatural T-cell) [54,111]
- dendritic cells [63]
Bacterial gene therapy
- recombinant idiotype Fab fragment [112]
- recombinant viral vector [87]
Immune cells
- peripheral gamma delta T cells [113]
- autologous cytokine induced killer (CIK) [114]
- natural killer (NK) [97]
- lymphokine activated killer (LAK) [11]
- activated CD8+ or CD4+  or CD3+  lymphocyte [115,116]
Peptide [117, 118]
Non-specific immunostimulatory factor (IL-2) [19]
operative remote infection such as pneumonia and surgical site infection when compared to
the control group.[11] In a study conducted on patients who underwent radical surgery for
colorectal cancer (Duke’ B and C), it was found that pre-operative interleukin-2 (IL-2)
administration had greatly reduced post-operative immunodeficiency with improved
prognosis. [12] This would be due to early activation of the antineoplastic immune system to
counteract the growth of minimal residue disease and prevent late disease progression.[12]
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Besides surgery,  radiotherapy is also an important treatment modality for cancer patients.
However, ionising radiation acts both as a carcinogen as well as a therapeutic agent.[13]
Besides the killing of cancer cells, it usually causes induction of intensive stress and DNA
damage to the surrounding tissues that lead to production of pro-inflammatory cytokines
including TGF-β,[14] reactive oxygen species (ROS),[13] epidermal growth factors and
fibroblast growth factors.[15] The series of these events may lead to persistence of
inflammatory reaction in the microenviromment and later carcinogenesis. [13] Thus, targeted
radiotherapy is essential to ensure the efficacy of treatment. Conjugation of tumour-
associated antigens (TAAs)-specific monoclonal antibodies with radioisotopes helped to
achieve a better response and prognosis.[16] Radioimmunotherapy of prostate cancer using
radiolabeled anti-prostate-specific membrane antigen monoclonal antibody (J591), showed
excellent targeting of soft-tissue and bone metastasis with limited toxicity of manageable
myelotoxicity.[17] A phase I/II clinical trial using the novel [131]I (iodine)-labeled Hab18G/
CD147-specific monoclonal antibody Fab’2 fragment on patients with hepatocellular
carcinoma has yielded an encouraging clinical outcome with improved survival rate of
progression-free in the patients after either one or two cycles of treatment (p<0.0001).[18]
CHALLENGES IN THE FIELD OF IMMUNOTHERAPY
The first mentioned immunotherapeutic approach using the non-specific immunostimulatory
agents including IFN-γ, IFN-α and rIL-2 has been associated with systemic toxicity and
autoimmune-like symptoms due to the over-activated immune system.[19, 20] Administration
of IL-2 in patients with advanced melanoma has shown no evidence of improved survival or
disease remission. [21] Toxicity complications caused by systemic administration of cytokines
such as IL-2 and IFN-α have been documented in patients with metastatic renal cell carcinoma,
[19]
 melanoma,[21] low-grade lymphoid neoplasm,[22] and prostate cancer.[23]
Despite the use of imuunostimulatory cytokines, monoclonal antibodies (mAbs), which
mainly target tumour associated antigens (TAAs), are also widely used in immunotherapy.
Tumour cells that are ‘tagged’ by the TAAs specific mAbs may help to recruit and provoke
host effector mechanisms to eradicate the targeted tumour cells.[9] However, some mAbs fail
to respond with expected outcomes such as, trastuzumab (anti-Her/2neu).[24] The failure of
antibody-based immunotherapy may mainly be due to low or loss of TAAs expression and
alteration of the immunodominant epitope.
The evolution of the immune evasion during tumorigenesis further complicates the
situation. Cancer immunoediting is a concept that focuses on the shaping of neoplasm and
has been proposed by Dunn et al. in 2002.[25] In this process, the immune system will first
undergo vigorous tumour killing, then come to the process of immune sculpturing to allow
the survival of low immunogenic tumour variants and finally lead to tumour escape
mechanism.[25] Down regulation or loss of TAA expression has been reported both in human
neoplasm and animal models such as melanoma,[26] colorectal carcinoma [27] and murine
retinoblastoma.[28] This phenomenon is often associated with repeated treatments [29] and
the presence of in vivo immunoselection pressure for immunoresistant tumor variants.[30, 31]
According to Matsui and colleagues, aggressive immunotherapy with peptide-stimulated
DUC18 T cells in tumours bearing BALB/c mice led to relapse of the disease with re-growth
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of tumour cells and loss of TAAs expression. [32] Other tumour escape mechanisms are
shown in Fig. 2.
The infiltration and priming efficiency of effector cells into the tumour micro-environment
may not guarantee anti-tumour immunity.[33, 34] The presence of large numbers of transgenic
or in-vitro expanded tumour antigen-specific T cells do not consistently cause regression
of tumour either in animals or patients.[35, 36, 37] It is most likely that this phenomenon may be
caused by the trafficking properties of the activated T cells as well as the tumour
environment.[38] Subpopulations of activated T cells may lose expression of CD62L and
CCR7 that enable them to adhere to the peripheral basement membrane[35] and trafficking
toward the inflammatory chemokine such as CCL3 and CCL5.[39, 40]
 The use of ex-vivo cultured effector cells and autologous tumour cells, which is the
third immunotherapeutic approach as mentioned earlier, is highly labour intensive. In addition,
these cells are not always successfully grown in vitro.[38] To generate effector cells for
adoptive transfer, novel cell culture methodologies are needed to improve the frequency of
specific T cells. Studies have shown that T cells isolated from different anatomical sites
including peripheral blood, solid tumour, liquid tumour, and tumour involved or tumour free
lymph nodes have different growth signals.[41] Tumour infiltrating lymphocytes (TILs) can
grow more consistently and to high levels than those isolated from peripheral blood. [41, 42]
These differences may be reflected by different maturation state, nature of antigenic stimulus,
frequency of re-stimulation, growth factors and co-stimulation of the T cells at different
sites including the expression of chemokine receptors.[43] As for adoptive transfer with
autologous tumour cells, large quantities of cells are needed. This attempt aims to immunise
the patient with all the antigens that are endogenously expressed by their tumour. [7] However,
some patients may have small tumour size and this can limit the quantity of cells available
for study. Thus, the procedure for expansion of cells will become too costly for the patients.
[7]
 In cases where the tumour lesion is not accessible, this approach will not be possible.
The presence of immunosuppressive cytokines such as, TGF-β and IL-10 within the
tumour (as shown in Fig. 2) may disturb the maturation of dendritic cells as well as effector
T cells generation and function.[44]  For example, injection of either apoptotic or non-apoptotic
tumour cells may not necessarily cause dendritic cell maturation but may provoke tolerance
of tumour immunity.[45, 46, 47] There are many other cells types, which may have immuno-
stimulatory effects, upon contact with apoptotic cells. Other than dendritic cells,
macrophages, which are more commonly present at the tumour site have the ability to
engulf apoptotic cells to cause secretion of a wide range of anti-inflammatory cytokines,
including interleukin (IL)-10 and TGF-β.[48, 49, 50]  In contrast, macrophages also respond to
non-apoptotic cells but to a lesser extent to produce pro-inflammatory cytokines such as
TNF-α and IL-1β.[48, 49, 50] Occasionally, apoptotic cells that have not been efficiently
phagocytosed may lead to secondary necrosis, which may cause autoimmunity. [51] A study
showed that mice bearing mutations resulting in defective phagocytosis of apoptotic cells
have a greater tendency to develop autoimmunity than the null type mice.[52] Therefore,
strategies to block phagocyte function or the inhibitory effect of cytokines produced during
phagocytosis have been carried out.  These apoptotic cells are found to be significantly
more immunogenic to the dendritic cells. [53]
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Figure 2. Proposed tumour escape mechanisms: (1) Local Dendritic cells (DCs) may be immature
and unable to up-take, process, or present antigens. These DCs may be inhibited from
migrating to regional lymph nodes or may actually induce tolerance, especially when
presenting self-antigens. (2) Regulatory T cells which infiltrate  the tumor site are able to
mediate suppression of antigen-primed T cells. (3) The presence of helper CD4 T cell
may skew the immune response toward a Th2 phenotype by secretion of Th2 cytokines
such as IL-6, TGF-β and IL-10. This phenomenon inhibits the initiation of Th1 T cells
and effective cellular immunity. (4) Tumor cells and the surrounding stromal may release
a number of suppressive cytokines such as IL-6, IL-10, and TGF-â. This creates an
environment that is not conducive to local immunity, which allows tumor cells to escape.
(5) Tumor cells may express aberrant MHC class I molecules or â2-microglobulins,
resulting in inadequate antigen presentation that prevent recognition of tumors by effector
T cells. (6) Mutations may cause aberrant gene expression in components of signaling
pathways as well as tumour antigen in tumour cells, resulting in abnormal cell behaviours
and inadequate antigen presentation to activate the effector T cells.
(Source: Adapted from www.innovitaresearch.org/news/04051401.html)
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STRATEGIES IN IMMUNOTHERAPY
Despite expression of a wide range of chemokines, cytokines with various immunomodulatory
effects have also being found. One possible explanation is that counteractive cytokines
such as TNF-α, IL-10, TGF-β are expressed simultaneously at the tumour site.  Thus,
activated effector cells are poorly attracted to the tumour site. To overcome this problem,
steps have been taken to block the inhibitory effect of the cytokine and to genetically
modify T cells to express a chemokine receptor for adoptive transfer has significantly
enhanced the T cell trafficking to the tumour and anti-tumour efficiency. [54] In addition,
modification of tumour cells to express CCL3 and CCL20 has generated effective anti-
tumour immune response. [44, 55, 56, 57] Therefore, a strategy to generate T cells with appropriate
trafficking properties as well as modification of the tumour cells may help to enhance the
efficiency of immunotherapy.
The efficiency of immunotherapy depends greatly on the recognition of antigen bearing
tumour cells by the antigen-specific effector population. Non-specific approaches to stimulate
the immune system have been carried out by using either autologous or allogenic tumour
cells expressing shared antigens, purified defined tumour antigens and epitopes have shown
some promising results in small trials. [58, 59, 60] Non-specific immunostimulatory agents,
including cytokines (IFN-γ and TNF-α), bacterial toxin (BCG) [3, 4] and immunostimulatory
mAbs [9] have been used to up-regulate the immunity of the patients. High-dose IFN-γ has
been used to treat patients with high-risk melanoma. [61] The tumoricidal ability of genetically
modified tumour cells and cytotoxic T-cells has been tested out recently in several clinical
trials. [62, 63]  Randomised clinical trials of autologous GM-CSF –producing prostate cancer
cells, APC8015 (Provenge) has demonstrated improved survival in patients with hormone-
refractory prostate cancer. [64]
In addition, several strategies have been formulated to overcome the toxic effect of
cytokine-based immunotherapy. O’Brien and colleagues have co-administered the rIL-2
with tauolidine in stage IV melanoma patients to reduce the toxicity without diminishing the
therapeutic effect. [65] In addition, ReGel, an aqueous-based polymer has been used as an
IL-2 delivery tool for cancer therapy. [66] The outcome of the study is very encouraging with
sustained IL-2 tumoricidal effect and decreased IL-2 toxicity. [66] In addition, selection of
alternative cytokines that have similar anti-tumour effect but lesser toxicity has been tested.
Oniki and colleagues have recently used a combination of two IL-12-related cytokines, IL-
23 and IL-27 to treat mice with poorly immunogenic B16F10 melanoma. Their study showed
that systemic administration of these cytokines induced a protective anti-tumour activity
which involved both the CD8+ T-cell and natural killer (NK) cells with minimal toxicity as
compared to IL-12 administration. [67] Furthermore, a novel cytokine molecule, which combines
desired cytokine activities to render toxic effect, has been developed by Acres & colleagues.
[68]
  An IL-2/IL-18 recombinant molecule which has a novel lymphocyte-stimulating activity
with reduced IL-2 associated toxicities in murine models has been tested. [68]
Lastly, aberrant expression of tumour-associated antigen in tumour cells has directed
the development of mAbs against cell-surface receptors of the immune system. [9] This
strategy helps to overcome the problem of loss or low antigen expression in tumour cells
and to boost or block the effects of immunosuppressive cytokines present in the tumour
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environment. [69] These immunostimulating antibodies are designed against a number of
molecules controlling the positive and negative signals in T cell activation. [70, 71] In animal
models, antibodies against CD40, [72] 4-1BB, [73] CTLA-4 [72, 74] and CD25 [75] have been
shown to provoke powerful tumour specific CTL responses capable of eradicating
established tumour mass.
CURRENT TRENDS IN IMMUNOTHERAPY
New combinational immunotherapies are currently being tested to improve the efficacy of
traditional treatment modalities. Combination of intratumoural dendritic cells with systemic
cytotoxic therapies, such as chemotherapy and radiotherapy, have been reported in several
studies. [76, 77, 78] In these models, the tumour cells were first killed by the chemotherapeutic
drugs which was followed by the administration of dendritic cells to react with the apoptotic
tumour cells to provoke anti-tumour immunity. [76, 77, 78] The combinational therapy was
significantly more effective than either agent alone. [76, 77, 78, 79] Using combinational therapy,
lower dose treatment regimens can be prescribed to the patients. [80] This innovative approach
helps to avoid the higher medication level that causes undesirable side-effects when a
single treatment modality is prescribed. [Please refer to Table 3 for the list of the clinical
trials involve combinational immunotherapy]
The issues of tumour immunosuppression and lack of identified tumour-associated
antigens (TAAs) are critical determining factors for successful immunotherapy. [81]  High
amounts of immunoregulatory lymphocytes (Treg), including CD4+CD25+ and
CD4+CD25+Foxp3+ subpopulations, IL-10 producing TR1 lymphocytes and tumour necrosis
factor beta (TGF-β) producing TH3 lymphocytes have been detected at the tumour
microenvironment which can inhibit the immune response and promote tumour outgrowth.
[82]
 In addition, high numbers of monocytes, macrophages and neutrophils have been
associated with very poor survival in patients with metastatic renal cell carcinoma. [83]
Several groups of researchers have developed therapeutic approaches based on the concept
of combinational immunotherapy to tackle these problems. For example, in patients with
Burkitt-type lymphoma (BL) or lymphoblastic leukemia (B-ALL), the use of hyper-
fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasome (hyper-CVAD)
together with rituximab (anti- CD20 monoclonal antibody) helped to achieve complete
remission in 86% (24/28) of the evaluated patients. [84] Chemotherapeutic drugs not only
eradicate tumour cell but they can also help to control Treg accumulation at the tumour
microenvironment. [85] At the same time, histamine, which can help to protect NK and T cells
against oxidative damage by inhibiting the formation and release of the phagocyte-derived
reactive oxygen species, can also be used for immunotherapy. [83] Co-administration of
histamine and IL-2 help to increase intratumoural CD56 NK cells (p= 0.008) and CD8+ T cells
(p= 0.019) with manageable toxicity compared to the baseline as well as treatment with IL-2
alone. [83] In an in vivo model of B16/BL6 melanoma, prescription of anti-CTLA-4 and a GM-
CSF- transduced tumour cell vaccine (Gvax) helped to change the intratumour balance of
Treg and effector T-cells to one which favors tumour rejection. [86] In this model, anti-CTLA-
4 prevents release of inhibitory substances on T cell activation and proliferation, whereas,
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Gvax primes the tumour-reactive effector T-cells which ultimately leads to T-cell activation
and proliferation.[86]
Another innovative approach to tackle the problem with immunodeficiency and
immunosuppression of patients is to up-regulate the immune system by using compounds
or fragments from microorganisms or recombinant bacterial or viral vectors.[87]  Local delivery
of vaccinia virus expressing multiple co-stimulatory molecules including B7.1 (CD80), ICAM-
1 and LFA-3 (rV-TRICOM) in patients with metastatic melanoma and breast cancer have
been shown to enhance T-cell responses to TAA to a level far greater than any one or two
applications of the co-stimulatory molecules in combination.[87, 88]  Recently, immunotoxin-
based therapy has been evaluated in several clinical trials in both haema-tological
malignancies and solid tumours.[89]  According to reports from several clinical trials, bacterial
toxin such as Diphteria toxin (DT, 580 amino acid) or Pseudomonas aeruginosa exotoxin A
(PE, 613 amino acid) that fused to the antibody Fv fragments has been shown to be a
powerful antibody with selectivity to cell killing.[89] Immunotoxins with anti-CD25 fused to
PE or DT was able to eliminate the Tregs population in the microenvironment, hence,
preventing immune tolerance.[90, 91]  According to results from meta-analysis of randomised
trials, intravesical BCG administration  effectively reduced the recurrence rate after
transurethral resection of patients with superficial bladder cancers.[92]
Strategies have been made to encounter the technical problem of how to deliver
molecules to the targeted destination. Dendritic cell transplantation has been widely used
to overcome this problem.  Autologous dendritic cells, which are extracted from the patients,
are cultivated together with the tumour-specific antigen to be injected back into the patients.
In order to further enhance the efficiency of this protocol, several groups have developed
ordinary differential equation (ODE) systems by using mathematical models to predict the
kinetics of the treatment, the influence of the treatment towards the normal physiologic
function and the optimal schedule of injection of an immunotherapeutic agent against
cancer.[80, 93]  These system characteristics are useful to gain a better understanding of the
dynamic of a tumour-specific system which can ultimately help to guide the development of
combinational therapies for elimination of the entire tumour.[80]
In addition, the choices of clinical adjuvants used for delivery of the therapeutic agents
to the target site are crucial. Due to the rapid degradation of the administrated immuno-
dominant epitopes from tumour associated antigens (TAAs) in vivo, the efficacy and
immunogenicity of the TAAs are low. Thus, this results in failure to mount an effective
immune response to the target tumour cells.[94] In addition, improper use of an adjuvant may
create undesirable secondary reactions that may increase the risk beneficial ratio for the
patients.[95] The use of lipid- based adjuvants including liposome, virosome, [94] oil in water
emulsion and bacterial immunostimulating compounds [95] have greatly enhanced the delivery
as well as the therapeutic efficiency of the therapeutic agents including TAAs-specific
peptides.[94]
CONCLUSION
Immunotherapy of cancer has re-emerged vigorously in the 1990s. More than 50
immunotherapeutic regimens are currently under clinical testing and more than 400 clinical
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trials have been conducted.[95] Nevertheless, the clinical outcome and the response rate of
the patients towards the testing agents are not sufficiently encouraging to prescribe it as a
standard treatment regimen in a clinical setting. Through fundamental basic research in
immunology, we will be able to figure out the ‘bad guy’ that is responsible for such a failure.
Immune dominant tolerance by regulatory T-cells and immuno-suppressive role of Th2
cytokines are some examples of tumour escape mechanisms. Researchers have found
numerous innovative approaches to overcome these barriers including the use of receptor-
specific monoclonal antibodies to block the suppressive effect of Treg (Intrabodies) and
the application of radio-labeled monoclonal antibodies to specifically guide the radioactive
treatment to the target tumour cells. Recently, the role of innate immune response in tumour
surveillance has been intensively studied. Clinical trials using natural killers against the
solid tumour has been conducted.[96]  The inherent complexity of the immune system as a
network of multiple interactions and redundant control loops amongst a huge diversity of
components may either create another barrier or open other options for immunotherapy. Re-
evaluation of previous clinical trials has suggested that combinational immunotherapy with
conventional cancer therapy have a better tumoricidal effect. A change in design and ultimate
goals of clinical trials will be needed to ensure long term disease stabilisation and a better
treatment outcome.
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